Streetbeat News

Price Targets

INVH

Invitation Homes (NYSE:INVH) has been evaluated by 7 analysts over the last three months, showing a mix of bullish to bearish sentiments. The recent ratings reveal a shift towards a more positive outlook, with an average 12-month price target of $38.43, up from $35.80. The company's financial performance indicates strong market position, revenue growth, and profitability, with a market capitalization surpassing industry averages and a net margin of 20.72%. Analysts' actions and price target adjustments reflect their response to the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:01 pm

BSX

17 analysts have provided mixed ratings for Boston Scientific (NYSE:BSX), with a recent shift towards more bullish perspectives. The average 12-month price target is now $69.24, marking a 10.78% increase from the previous target. Analysts have adjusted their ratings and price targets, reflecting optimism about the company's performance. Boston Scientific, known for its less invasive medical devices, has shown a positive revenue trend with a 14.9% growth rate as of December 31, 2023, but faces challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:00 pm

CPRX

B of A Securities analyst Jason Gerberry initiates coverage on Catalyst Pharmaceuticals with a Buy rating and a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 4:00 pm

AZTA

Azenta (NASDAQ:AZTA) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target for AZTA has increased to $75.00, reflecting a 9.76% rise from the previous target. Financial analysis reveals challenges in revenue growth and asset utilization, but efficient cost management and low debt reliance are positive indicators. Azenta specializes in life sciences solutions, with significant revenue from its Life Sciences Services segment.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 4:00 pm

NIO

NIO shares are trading lower following a price target reduction by Bernstein from $7.50 to $5.50.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:59 pm

PEPG

PepGen's stock is trading lower following the announcement of its Q4 earnings per share (EPS) results. Additionally, Wedbush has maintained an Outperform rating on PepGen but reduced its price target from $21 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:59 pm

TPVG

Compass Point analyst Casey Alexander downgrades TriplePoint Venture Growth (TPVG) from Neutral to Sell with a new price target of $8.75.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:55 pm

CCOI

B of A Securities analyst David Barden downgraded Cogent Communications Holdings (CCOI) from Buy to Neutral and reduced the price target from $85 to $75.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:54 pm

EVGO

Cantor Fitzgerald analyst Andres Sheppard downgraded EVgo (NASDAQ:EVGO) from Overweight to Neutral and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:52 pm

ALNT

Northland Capital Markets analyst Ted Jackson downgrades Allient (NASDAQ:ALNT) from Outperform to Market Perform and lowers the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:49 pm